Short Interest in Apollomics Inc. (NASDAQ:APLM) Grows By 104.5%

Apollomics Inc. (NASDAQ:APLM) saw a large growth in short interest in June. As of June 30th, there was short interest totaling 5,144 shares, a growth of 104.5% from the June 15th total of 2,515 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average trading volume of 21,851 shares, the short-interest ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC purchased a new stake in shares of Apollomics Inc. (NASDAQ:APLM) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics at the end of the most recent reporting period. 19.13% of the stock is currently owned by institutional investors and hedge funds.

Apollomics Stock Down 2.7%

Shares of APLM stock opened at $18.67 on Thursday. Apollomics has a 52-week low of $3.66 and a 52-week high of $42.12. The firm’s 50-day moving average is $16.27 and its 200-day moving average is $17.55.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.